Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Synthesis

Tree Bark Inspires Vaccine Adjuvants

Synthetic saponin analogs have potential to improve immune response to vaccines and thus improve vaccine efficacy

by Sophie L. Rovner
February 8, 2010 | A version of this story appeared in Volume 88, Issue 6

Vaccine Enhancers
[+]Enlarge
Credit: J. Am. Chem. Soc.
These semisynthetic saponin adjuvants are more stable than the bark-derived natural saponin that inspired them. Me = methyl.
Credit: J. Am. Chem. Soc.
These semisynthetic saponin adjuvants are more stable than the bark-derived natural saponin that inspired them. Me = methyl.

Weak antigens used in antitumor and antiviral vaccines often require an adjuvant, a substance that helps stimulate enough of an immune response to make the vaccine effective. But few such adjuvants are currently available. David Y. Gin and colleagues at Memorial Sloan-Kettering Cancer Center, in New York City, are reporting some new compounds that could extend the family of vaccine adjuvants (J. Am. Chem. Soc., DOI: 10.1021/ja9082842). The team was inspired by QS-21, a saponin natural product obtained from bark extracts of the South American tree Quillaja saponaria. QS-21, which consists of a triterpene, a branched trisaccharide, and a glycosylated acyl chain, is a potent adjuvant but hasn’t been commercialized because it’s unstable, scarce, difficult to purify, and toxic in large doses. Gin and coworkers overcame these problems by designing QS-21 analogs in which they replaced unstable ester linkages in the acyl chain with stable amide linkages. The three new compounds, which are prepared by a semisynthetic route, are potent adjuvants—and two of them are less toxic than QS-21. The researchers conclude that QS-21 analogs don’t need to be as complex as the original saponin to be effective and that the toxicity can be separated from efficacy.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.